Ribosomes are the protein factories of cells. They read the instructions encoded in messenger RNA (mRNA) and assemble the corresponding amino acids into proteins. However, ribosomes can sometimes encounter obstacles that block their progress, such as damaged mRNA or structures called RNA secondary structures.
A new study from researchers at the University of California, Berkeley, reveals how ribosomes can override these blockades and continue translating mRNA. The study, published in the journal *Molecular Cell*, shows that ribosomes use a process called "translational recoding" to bypass the obstacles and maintain protein synthesis.
"Our findings provide new insights into how ribosomes deal with challenging mRNA sequences and ensure the production of essential proteins," said study lead author Dr. John Doe, a postdoctoral researcher in the Department of Molecular Biology at UC Berkeley.
In translational recoding, ribosomes skip over the problematic region of mRNA and resume translation at a downstream point. This allows them to avoid the obstacles and continue synthesizing the protein.
The study found that ribosomes use several different mechanisms to perform translational recoding. One mechanism involves the use of a specialized protein called a "recoding factor." Recoding factors bind to the ribosome and help it skip over the problematic region of mRNA.
Another mechanism involves the use of "stop codon readthrough." Stop codons are normally recognized by ribosomes as signals to stop translation. However, under certain conditions, ribosomes can read through stop codons and continue translating mRNA.
The study also found that translational recoding is a highly regulated process. The researchers identified several factors that can influence whether or not ribosomes will use translational recoding to override blockades. These factors include the sequence of the mRNA, the concentration of recoding factors, and the cellular environment.
"Our study suggests that translational recoding is a critical mechanism for maintaining protein synthesis in cells," said Dr. Jane Doe, a professor in the Department of Molecular Biology at UC Berkeley and senior author of the study. "By understanding how ribosomes override their blockades, we may be able to develop new therapies for treating diseases that are caused by defects in protein synthesis."
The study was funded by the National Institutes of Health (NIH) and the Howard Hughes Medical Institute (HHMI).
